South Korea to Pump US$1 Bln Into Drug Sector to Brace for FTAs (South Korea)
This article was originally published in PharmAsia News
Executive Summary
South Korea's government plans a 10-year, approximately $1.07 billion investment in its pharmaceutical industry to prepare for global trade rules under a U.S.-South Korea Free Trade Agreement (FTA). Analysts believe South Korea's domestic drug industry will lose around 168.8 billion won annually to tough U.S. competition if FTA rules are implemented. (Click here for more
You may also be interested in...
South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers
SEOUL - South Korean pharmaceutical companies are bracing for a tough time ahead if the governments of South Korea and the U.S. ratify a long-awaited Free Trade Agreement hammered out last year after eight rounds of negotiations between the two countries
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.